Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Int J Mol Sci. 2023 Sep 6;24(18):13767. doi: 10.3390/ijms241813767.
Thyroid cancer has become more common in recent years all around the world. Many issues still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid cancer. Liquid biopsy (mainly circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating exosomes) may provide a novel and ideal approach to solve these issues, allows us to assess the features of diseases more comprehensively, and has a function in a variety of malignancies. Recently, liquid biopsy has been shown to be critical in thyroid cancer diagnosis, treatment, and prognosis in numerous previous studies. In this review, by testing CTCs, ctDNA, and exosomes, we focus on the possible clinical role of liquid biopsy in thyroid cancer, including diagnostic and prognostic biomarkers and response to therapy. We briefly review how liquid biopsy components have progressed in thyroid cancer by consulting the existing public information. We also discuss the clinical potential of liquid biopsy in thyroid cancer and provide a reference for liquid biopsy research. Liquid biopsy has the potential to be a useful tool in the early detection, monitoring, or prediction of response to therapies and prognosis in thyroid cancer, with promising clinical applications.
近年来，甲状腺癌在全球范围内变得更为常见。在甲状腺癌的诊断、治疗和预后方面，仍有许多问题亟待解决。液体活检（主要是循环肿瘤 DNA（ctDNA）、循环肿瘤细胞（CTC）和循环外泌体）可能为解决这些问题提供一种新颖且理想的方法，使我们能够更全面地评估疾病的特征，并在多种恶性肿瘤中发挥作用。最近，多项研究表明，液体活检在甲状腺癌的诊断、治疗和预后中具有重要作用。在本综述中，我们通过检测 CTCs、ctDNA 和外泌体，重点关注液体活检在甲状腺癌中的可能临床作用，包括诊断和预后生物标志物以及对治疗的反应。我们通过查阅现有公开信息，简要回顾了液体活检成分在甲状腺癌中的进展情况。我们还讨论了液体活检在甲状腺癌中的临床应用潜力，为液体活检研究提供了参考。液体活检有可能成为甲状腺癌早期检测、监测或预测治疗反应和预后的有用工具，具有广阔的临床应用前景。
Zotero 插件
